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Abstract
Background: Antimicrobial resistance is a public-health threat and antimicrobial consumption is the main
contributor. The ten-valent pneumococcal conjugate vaccine (PHiD-CV10) was introduced into the Icelandic
vaccination program in 2011.
The aim was to estimate the vaccine impact of PHiD-CV10 on outpatient antimicrobial prescriptions in children.
Methods: Eleven Icelandic birth-cohorts (2005–2015) were followed from birth until three years of age or to the end of
the study period (December 31, 2016). Birth-cohorts were grouped as vaccine non-eligible (VNEC, 2005–2010)
or vaccine eligible (VEC, 2011–2015). Data on primary care visits for respiratory infections and antimicrobial
prescriptions were extracted from two national registers. Using national identification numbers, prescriptions
were linked to physician visits if filled within three days of the visit. Incidence rates and incidence rate ratios
between VNEC and VEC were calculated. An Andersen-Gill model was used to model the individual level data,
accounting for repeated events and censoring. Vaccine impact was calculated as (1 – Hazard Ratio) × 100%.
Results: Included were 53,510 children who contributed 151,992 person-years of follow-up and filled 231,660
antimicrobial prescriptions. The incidence rate was significantly lower in the VEC compared to the VNEC, 144.5
and 157.2 prescriptions per 100 person-years respectively (IRR 0.92, 95%CI 0.91–0.93). Children in VEC were
more likely to have filled zero (IRR 1.16 (95%CI 1.10–1.23) and 1–4 (IRR 1.08 95%CI 1.06–1.11) prescriptions
compared to children in VNEC. The vaccine impact of PHiD-CV10 against all-cause antimicrobial prescriptions
was 5.8% (95%CI 1.6–9.8%).When only considering acute otitis media-associated prescriptions, the vaccine
impact was 21.8% (95%CI 11.5–30.9%).
Conclusion: The introduction of PHiD-CV10 lead to reduced antimicrobial use in children, mainly by reducing
acute otitis media episodes. This intervention therefore reduces both disease burden and could slow the spread of
antimicrobial resistance.
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Background
Acute otitis media (AOM) and other upper respiratory
tract infections (URTI) are the most common causes of
ambulatory physician visits and antimicrobial prescrip-
tions in children [1, 2]. The most common bacterial
causes of URTI in young children are Streptococcus
pneumoniae and Haemophilus influenzae, though most
are caused by viral pathogens [3–6]. Distinguishing be-
tween viral and bacterial URTI can be difficult. As much
as 30–50% of outpatient antimicrobial prescriptions for
URTI are inappropriate [2, 7, 8]. Physicians cite the un-
certainty of diagnosis and fear of disease complications
as two important factors contributing to inappropriate
prescriptions [2, 9–11], which in turn increases anti-
microbial resistance [12, 13].
Antimicrobials were once universally recommended in
the treatment of AOM to prevent complications. How-
ever, when several studies showed no increase in compli-
cations in populations with lower prescription rates [2,
14], this endorsement came under scrutiny. As a result,
guidelines which recommended more restrictive pre-
scription practices to combat rising antimicrobial resist-
ance were adopted in many countries in the early 2000s
[14–17]. This has led to a subsequent decrease in anti-
microbial consumption [14, 16, 18, 19].
Concurrently, pneumococcal conjugate vaccines (PCV)
were widely introduced into paediatric vaccination pro-
grams and have been associated with a decrease in AOM
incidence [1, 18, 20–23]. Several randomized controlled
trials (RCT) of PCVs have also shown a decrease in both
all-cause and URTI-associated antimicrobial prescription
rates [24–26].
The 10-valent pneumococcal non-typeable Haemophi-
lus influenzae protein D-conjugate vaccine (PHiD-CV10,
Synflorix™) was introduced into the Icelandic paediatric
vaccination program, with a 2 + 1 schedule without a
catch-up for all children born in 2011 and later. Follow-
ing the introduction, over 97% of each vaccine eligible
birth-cohort received ≥2 doses of the vaccine [27]. Prior
to the introduction of PHiD-CV10, few children were
vaccinated, 0–1.9% of birth-cohorts, while 6.9% and
18.7% of children in birth-cohorts 2009 and 2010 re-
ceived ≥2 doses [27].
The aim of this study was to investigate the impact of
PHiD-CV10 against outpatient antimicrobial prescrip-
tions for children < 3 years of age in Iceland.
Methods
Data sources
The study is a whole population observational cohort
study of all children under three years of age in Iceland.
Eleven consecutive birth-cohorts 2005–2015 were
followed until three years of age or to the end of the study
period, December 31, 2016. Individual level data on
immigration and emigration was obtained from Statistics
Iceland. Children who immigrated to Iceland after birth
were excluded from the analysis. Observations were cen-
sored on death or emigration from Iceland. The 2016
birth-cohort was not included due to short follow-up
time.
Data on outpatient antimicrobial prescriptions was ex-
tracted from the National Prescription Database (NPD)
of the Directorate of Health. The NPD receives auto-
mated electronic data from all pharmacies in Iceland,
and registers detailed information on each outpatient
prescription in the country, identifiable down to the in-
dividual and day of purchase. All drug prescriptions with
the anatomical therapeutic chemical (ATC) classification
code J01 (antibacterials for systemic use) and subgroups
were extracted from the NPD.
Information regarding primary care visits for respira-
tory tract infections was obtained from the Primary Care
Database of the Directorate of Health. All visits with
International Classification of Diseases, 10th Revision
(ICD-10) discharge diagnoses compatible with respira-
tory tract infections were extracted as previously de-
scribed [23]. This data was linked to the NPD using
national identification numbers. Prescriptions were
paired with a physician visit if filled for the same child
within three days of the visit. Data from the Primary
Care Database was available only through December 31,
2015, restricting the use of linked data to that date. In-
formation on population demographics was acquired
from Statistics Iceland (https://www.statice.is/).
Statistical analysis
The study analysis was done by comparing birth-cohorts
individually or grouped by vaccine eligibility. Individual
birth-cohorts were each compared to the last vaccine
non-eligible birth-cohort (2010) which was used as a ref-
erence cohort. Birth-cohorts 2011–2015 were grouped
as the vaccine-eligible cohorts (VEC) and birth-cohorts
2005–2010 as the vaccine non-eligible cohorts (VNEC).
Aggregate analyses by calendar year were performed
for all children under three years of age. Antimicrobials
were classified into six classes; first and second line pen-
icillins, first and second generation macrolides, cephalo-
sporins and others (Table 1) [28]. The proportion of
antimicrobial prescriptions in each class was calculated
by calendar year. Similarly, the proportion of primary
care visits resulting in antimicrobial prescription in each
calendar year was calculated by indication. Five groups
were defined based on ICD-10 discharge diagnosis;
Acute upper respiratory infections (J00-J06), Influenza
and pneumonia (J09-J18), Other acute lower respiratory
infections (J20-J22), AOM (H65, H66 and H72) and
Other viral infections (B34).
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Crude incidence analysis
Incidence rates (IR) per 100 person-years at risk for each
of the study birth-cohorts were calculated in six-month
age-groups and 95% confidence intervals estimated using
the Wald method. Incidence rate ratios (IRR) between
the VNEC and the VEC were estimated and 95% confi-
dence intervals calculated assuming Poisson variance.
The cumulative proportion of outpatient antimicrobial
prescriptions by three years of age was compared
between VNEC and VEC using the Chi-squared test of
homogeneity. For this analysis, the 2014 and
2015-cohorts were excluded as they did not have the full
three-year follow-up time. The cumulative number of
outpatient antimicrobial prescriptions per child was
stratified into brackets < 1, 1–4, 5–9, 10–14 and ≥ 15
and the incidence risk ratio between VNEC and VEC
was calculated for each bracket.
Regression analysis
The Andersen-Gill extension of the Cox [29] regression
model for repeated events was used to model the indi-
vidual level data and allow for censored follow-up times.
The model included age as the underlying measure of
time to directly correct for age and was stratified allow-
ing different baseline-hazards for each gender. The cu-
mulative number of previous antimicrobial prescriptions
was included as a covariate and modelled using a re-
stricted cubic spline relationship. Finally, birth-cohort
membership was included as a categorical variable. Ro-
bust sandwich variance estimates were included to ac-
count for correlation between successive observations of
the same child. The model was used to estimate the haz-
ard ratio (HR) of antimicrobial prescription between
each of the study birth-cohorts and the reference
birth-cohort. The vaccine impact of PHiD-CV10 in re-
ducing outpatient antimicrobial prescriptions was then
estimated as 1 – (the hazard ratio between the last vac-
cine eligible cohort and the reference cohort) × 100%.
The vaccine impact against each successive prescrip-
tion was estimated by calculating the hazard ratio of
antimicrobial prescription between VEC and VNEC for
each number of previous prescriptions.
Finally, the mean number of antimicrobial prescrip-
tions for each gender and vaccine-cohort was calculated
as a function of age using the generalized Nelson-Aalen
estimate [29]. This was used to estimate the absolute
number of prevented antimicrobial prescriptions during
the first seven years of the intervention by adding to-
gether the expected number of prescriptions per child
using the VNEC estimate of the mean and subtracting
the expected number of prescriptions per child using the
VEC estimate of the mean. The absolute rate reduction
was calculated by dividing this estimate with the number
of person-years at-risk in the VEC.
A sub-analysis was performed to estimate the vaccine
impact against AOM-associated antimicrobial prescrip-
tions. The same regression methodology was applied to
a subset of the prescriptions which were linked to a pri-
mary care physician visit with a diagnosis of AOM.
Vaccine impact was similarly estimated as 1 – (the haz-
ard ratio between the last vaccine eligible cohort and the
reference cohort) × 100%.
Results
Population
Information was available for 53,218 children born from
2005 to 2015. Children who immigrated to Iceland
(1892) were excluded from the analysis. An additional
756 children were excluded due to lack of information
on gender or date-of-birth. The remaining 50,570 chil-
dren were followed for a total of 140,429 person-years
and accumulated 226,181 antimicrobial prescriptions. Of
the children who had a full three-year follow-up time,
the median number of prescriptions per child was 4 pre-
scriptions (IQR 2–7, range 0–55). Person-years at-risk
by age-group for children in the VNEC and VEC is
shown in Table 3.
Antimicrobial usage
First-line penicillins were the most commonly prescribed
antimicrobials in 2005–2012 and represented between
41 and 47% of all prescriptions. In 2013, their use de-
creased to 32% and in 2014 and 2015 to 18%. In 2016, it
increased to 35%. Concurrently, the use of second-line
penicillins increased from 35 to 40% in 2005–2012, to
48%, 55%, and 54% in 2013, 2014 and 2015 respectively,
before decreasing to 42% in 2016. The use of cephalo-
sporins was 5.2–7.8% in 2005–2012 and increased to
10–15% in 2013–2016. Use of macrolides and other anti-
microbials can be seen in Table 2.
Crude incidence rate and incidence rate ratios
The overall crude rate of antimicrobial prescriptions for
children < 3 years of age was significantly lower in the
VEC than the VNEC, 150.3 and 167.6 antimicrobial pre-
scriptions per 100 person-years respectively (IRR 0.90,
95%CI 0.89–0.91). The crude incidence per six-month
age-groups are shown in Table 3. The crude incidence
Table 1 Classification of antimicrobials used in this study
First-line penicillins Amoxicillin, phenoxymethylpenicillin
Second-line penicillins Amoxicillin and enzyme inhibitor
First-generation macrolide Erythromycin
Second-generation macrolide Azithromycin, clarithromycin,
Cephalosporin Cefalexin
Others Ciprofloxacin, clindamycin, pivmecillinam,
Trimethoprim/sulfmethoxazole,
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rate was highest among children 12–17 months of age in
both VNEC and VEC, 247 and 233 prescriptions per 100
person-years respectively. The incidence rate of prescrip-
tions decreased in all age-groups (IRR 0.82–0.94) with
the largest decrease (IRR 0.82, 95%CI 0.79–0.85) in chil-
dren < 6 months of age (Fig. 1).
The crude cumulative proportion of antimicrobial pre-
scriptions at three years of age was 86.7% and 84.9% for
the VEC and VNEC. A significantly larger proportion of
children in the VEC had 0 or 1–4 prescriptions com-
pared to children in the VNEC (incidence risk ratios
1.13, 95%CI 1.06–1.21 and 1.08, 95%CI 1.05–1.11 re-
spectively). Concurrently, the proportion of children
who filled ≥5 prescription decreased (Table 4).
The proportion of visits due to AOM which resulted
in an antimicrobial prescription increased gradually
2005–2015 from 57 to 64% (Additional file 1: Figure S1).
The incidence rate of AOM-associated prescriptions de-
creased from a high of 54.9 prescriptions per 100
person-years in 2008 to 39.8 prescriptions per 100
person-years in 2015. The crude incidence rates of
AOM-associated prescriptions by six-month age-groups
are shown in Table 3. Concurrently, the proportion of
AOM-associated antimicrobial prescriptions, out of all
linked prescriptions remained stable between 59 and
66% (Fig. 2, Additional file 2: Table S1). Similarly, the in-
cidence and proportion of visits due to acute upper re-
spiratory infections which resulted in a antimicrobial
prescription, increased from 2005 to 2008 after which it
plateaued (Fig. 2 and Additional file 2: Table S1).
Individual level regression modelling of all-cause
antimicrobial prescriptions
No significant deviation from model assumptions was
noted in model diagnostic testing. The hazard of filling an
antimicrobial prescription was significantly higher in the
first three VNEC compared to the reference cohort (HR
1.08 95%CI 1.05–1.13, HR 1.12 95%CI 1.07–1.15) and HR
1.05 95%CI 1.01–1.09 respectively) while the hazard of
birth-cohorts 2008 (HR 1.02 95%CI 0.98–1.06) and 2009
(HR:1.02 95%CI 0.98–1.06) did not differ from it signifi-
cantly. Conversely, each vaccine-eligible birth-cohorts
Table 2 Number of prescription per calendar year for children < 3 years of age and the proportion of each antimicrobial class
Calendar year Incidence of prescriptions









Cephalosporins (%) Other (%)
2005 204 (25649) 41.41 37.92 1.48 6.55 5.37 7.26
2006 205 (26396) 40.34 39.57 1.27 6.22 5.36 7.24
2007 192 (25179) 44.97 36.80 1.60 6.39 5.16 5.08
2008 178 (24046) 46.74 35.22 0.20 6.37 5.91 5.57
2009 159 (22406) 46.41 37.16 0.05 5.51 6.33 4.55
2010 167 (24007) 43.71 38.55 0.02 5.54 7.02 5.17
2011 164 (23866) 44.70 37.92 0.03 5.91 7.47 3.98
2012 160 (22703) 43.45 39.01 0.01 6.92 7.77 2.83
2013 152 (21113) 32.10 48.08 0.02 6.56 10.03 3.20
2014 152 (20325) 18.48 55.46 0.01 6.60 14.53 4.92
2015 150 (19873) 18.49 53.91 0.06 7.25 14.95 5.34
2016 160 (20543) 35.28 41.68 0.04 5.52 12.91 4.57
Table 3 Incidence rate (IR) of all-cause and AOM-associated antimicrobial prescriptions per 100 person-years, comparing the Vaccine
non-eligible cohorts (born 2005–2010, VNEC) to the Vaccine eligible cohorts (born: 2011–2015, VEC). aPrimary care data was only
available until December 31st 2015. Therefore fewer person-years at-risk were available for the VEC when considering AOM-




IR (n of prescriptions) Person-years at-risk IR (n of prescriptions) Person-years at-risk
All cause AOM-associated All cause AOM-associated
< 6 47.0 (6816) 11.6 (1681) 14,491 39.1 (4338) 7.58 (813) 11,096a
6–11 206 (29,674) 69.1 (9931) 14,378 176 (19,447) 52.5 (5045) 11,024a
12–17 247 (35,226) 72.9 (10,372) 14,233 233 (24,588) 62.2 (5295) 10,566a
18–23 199 (28,008) 49.9 (7309) 14,096 189 (17,876) 46.6 (3411) 9460a
24–29 164 (22,843) 35.0 (4882) 13,965 144 (12,069) 30.3 (1882) 8374a
30–35 125 (17,259) 24.1 (3331) 13,848 112 (7218) 21.1 (1074) 7218a
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exhibited significantly lower hazard as compared to the
reference cohort, with hazard ratios ranging from 0.90–
0.94 (Fig. 3). The estimated PHiD-CV10 vaccine impact
against all-cause antimicrobial consumption was 5.8%
(95%CI 1.6–9.8%).
The hazard of receiving an additional antimicrobial pre-
scription increased with each prescription, with the stee-
pest increase following the first three prescriptions. The
vaccine was associated with a significantly lower hazard of
filling the first (HR 0.88, 95%CI 0.87–0.90), second (0.94
HR 0.92–0.96) and third (HR 0.97, 95%CI 0.95–0.99) pre-
scriptions, but no significant difference was noted in the
hazard of filling subsequent prescriptions.
The mean number of prescriptions in the first three
years of life is displayed in Fig. 4. At 36 months of age, the
mean number of prescriptions decreased from 6.07
(95%CI 6.00–6.14) to 5.46 (95%CI 5.38–5.55) among girls
and from 6.48 (95%CI 6.42–6.55) to 5.84 (95%CI 5.76–
5.93) among boys, in the VNEC and VEC respectively.
The estimated absolute number of prevented prescriptions
in the first six years of the intervention was 12,612 (95%CI
9471-15,752) with an absolute incidence rate reduction of
22.0 (95%CI 16.5–27.5) antimicrobial prescriptions per
100 person-years.
In the sub-analysis for AOM-associated antimicrobial
prescriptions vaccine impact was calculated to be 21.8%
(95%CI 11.5–30.9%), Additional file 3: Figure S2 shows
HRs for each of the birth-cohorts compared to the
2010-reference cohort.
Discussion
This population based study of 11 consecutive birth-co-
horts followed until three years of age demonstrates a
5.8% reduction in all-cause outpatient antimicrobial pre-
scriptions associated with the inclusion of PHiD-CV10
into the national paediatric vaccination program. We
show that a relatively stable proportion of AOM visits
result in antimicrobial prescriptions and that AOM is
the most common indication for antimicrobial prescrip-
tions in this age group. The impact of PHiD-CV10 on
AOM-associated antimicrobial prescriptions was esti-
mated 21.8%. Our group has previously demonstrated a
22% reduction in AOM visits following PHiD-CV10
introduction in Iceland [23]. Thus, a reduction in AOM
episodes is a likely explanation for the reduction in
all-cause antimicrobial prescriptions noted in this study.
Age specific incidence rates of antimicrobial prescrip-
tions were calculated for each birth-cohort and show a
significant decrease in prescriptions in all age-groups
following vaccine introduction. Also, the mean number
Fig. 1 Incidence rate (IR) of antimicrobial prescriptions per 100 person-years for each birth-cohort for each of the six age groups as columns, blue
for the vaccine non-eligible cohorts (NVEC, born 2005–2010) and red for the vaccine eligible cohorts (VEC, born 2011–2015). Error bars represent
95% confidence interval for IR. Incidence rate ratio (IRR) between the VNEC and VEC with 95% confidence intervals are displayed at the end of
the columns
Table 4 The proportion and 95% confidence interval for the
vaccine non-eligible cohorts (VNEC, born: 2005–2010) and the
vaccine eligible cohorts (VEC, born 2011–2013) that had filled
0, 1–4, 5–9, 10–14 and≥ 15 prescriptions at 36 months of age.
Only children with full 36 months follow-up were included
Number of
prescriptions
Incidence proportion (%) Incidence risk ratio (95%CI)
VNEC VEC
0 11.4 13.2 1.16 (1.10–1.23)
1–4 43.7 47.3 1.08 (1.06–1.11)
5–9 31.6 29.1 0.92 (0.89–0.95)
10–14 9.8 7.5 0.77 (0.72–0.82)
≥15 3.5 2.9 0.83 (0.74–0.93)
Total 100 100
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Fig. 2 Antimicrobial prescriptions are linked to primary care visits if filled within three days of the index visit. Both graphs represent children < 36 months
of age and are shown by calendar year. a represents the proportion of all antimicrobial prescriptions which were associated with a primary care visit due
to a specific diagnostic group. b represents the incidence of antimicrobial prescriptions per 100 person-years which were associated with
a diagnostic group
Fig. 3 The hazard ratio (HR) from the cox-regression model for each of the study birth-cohorts compared to the last vaccine non-eligible birth-cohort
(2010), the reference birth-cohort. Boxes represent point estimates for HR and lines the 95% confidence intervals
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of outpatient antimicrobial prescriptions for both the
VNEC and VEC was estimated as a function of age and
a significant decrease in both genders was demonstrated.
RCT have shown significant vaccine efficacy of PCVs
against outpatient antimicrobial consumption, with out-
comes ranging from 5.4% (95%CI 4.0–6.7) [25] to 8%
(95%CI 1–14) [26] and 15% (95%CI 3–25) [24]. Our re-
sults are within the lower bounds of these findings.
Though blinded RCT provide robust estimates of vac-
cine efficacy, they do so under artificial conditions. Par-
ents and physicians may behave differently knowing that
their actions are being observed and quantified by re-
searchers, and this may reduce the incidence of inappro-
priate prescribing. Observational studies are valuable in
demonstrating that vaccine impact against outpatient
antimicrobial prescriptions can still be observed in true
clinical settings. Several observational studies have previ-
ously assessed the change in antimicrobial prescriptions
following PCV introduction, demonstrating a 20–42%
decrease in AOM-associated prescriptions in children <
2 years of age [8, 21] and a 5–24% decrease in all-cause
antimicrobial prescriptions in older children [30, 31].
These findings are in agreement with our results.
The present study has several strengths, chiefly in the
inclusion of the whole population of children under
three years of age. Because all Icelandic children in 11
consecutive birth-cohorts are included, the possibility of
sampling bias is eliminated. In Iceland, antimicrobials
for systemic use are exclusively available by physician
prescription. When a prescription is dispensed at any
pharmacy in Iceland, information about the prescription
is sent electronically to the NPD. The prescription is
linked to the individual child’s national identification
number which allows observation of prescriptions by in-
dividual children regardless of location or time.
By using all-cause antimicrobial consumption as the out-
come measure without attempting to exclude cases unlikely
to be attributable to diseases caused by pneumococci, no
positive bias is introduced through case ascertainment. The
fact that antimicrobial consumption in Iceland is close to
the average for European countries [32] further generalizes
the results of the study.
The PHiD-CV10 was introduced in 2011 into the rou-
tine childhood vaccination program without a catch-up
schedule. The uptake was immediately high with over 97%
of each vaccine eligible birth-cohort receiving ≥2 doses
[27]. Prior to the introduction of PHiD-CV10, no system-
atic vaccination against pneumococcus was in place. Be-
tween 0 and 1.9% of birth-cohorts 2005–2008 received ≥2
doses of PCV, and this proportion increased to 6.9% and
18.7% in birth-cohorts 2009 and 2010 [27]. The increase
in vaccine uptake in birth-cohorts 2009 and 2010 is likely
due to heightened awareness of the impending inclusion
of PHiD-CV10 into the vaccination program, with many
parents and caregivers opting to pay out-of-pocket for the
vaccine. This clear differentiation in vaccine coverage be-
tween the vaccine non-eligible birth-cohorts and vaccine
eligible birth-cohorts permits the use of the cohorts as a
proxy for vaccination status.
Finally, as the data was identifiable to the individual, it
allowed the use of more sophisticated survival analysis
methods which are normally reserved for non-observa-
tional studies. This allowed for the complex interaction
between age, gender and the number of previous anti-
microbial prescriptions to be considered when estimat-
ing the vaccine impact. A crude incidence rate analysis
was also performed (Fig. 1). Such an analysis necessitates
the creation of discrete age-groups for comparison as
the incidence of antimicrobial prescription varies by age
and some of the VEC have censored follow-up time. The
Fig. 4 Expected mean number of prescription per child for the vaccine non-eligible cohorts (VNEC, born 2005–2010) and the vaccine eligible cohorts
(VEC, born 2011–2015), for both genders from birth to third birthday. Lines represent point estimates and shaded area the 95% confidence intervals
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results of the individual level analysis demonstrate that
the vaccine decreased the risk of the first, second and
third antimicrobial prescriptions. However, the vaccine
was not associated with a further decrease in risk in
those who had already filled ≥4 prescriptions. This pro-
vides evidence for a cumulative effect and is congruent
with the results of the crude incidence analysis where
the difference is most evident in the older age-groups.
Because age is discretized in the crude analysis, the cu-
mulative effect is not estimated and the vaccine impact
is less apparent. Using the individual level analysis, it
was also possible to demonstrate the mean number of
prescriptions by age, taking gender, vaccine eligibility
and number of previous prescriptions into account.
Interestingly, antimicrobial consumption was signifi-
cantly higher in boys than girls. The mean number of
prescriptions for boys decreased significantly following
vaccine introduction, becoming the same as that of girls
prior to the vaccination (Fig. 4). This gender difference
may be attributed to the fact that AOM is more com-
mon in boys than girls [33].
When children in the VEC were stratified by vaccin-
ation status, rather than birth-cohort, an abnormally
high proportion of children who neither visited a phys-
ician nor filled an outpatient antimicrobial prescription
was concentrated among those who did not have a doc-
umented vaccine dose. This is likely due to either under
documentation of administered vaccine doses or chil-
dren emigrating from Iceland without an official change
in legal residence. Children who are for any reason un-
able to experience the study event, i.e. fill an outpatient
antimicrobial prescription, are for the same reason likely
to be unable to have a documented administered vaccine
dose. This precluded an analysis using individual vaccin-
ation status to directly estimate the vaccine impact.
A significant downward trend in antimicrobial con-
sumption was noted during the pre-vaccination era, with
the final VNEC having significantly lower consumption
than birth-cohorts 2005–2007 and non-significantly less
consumption than birth-cohorts 2008 and 2009. Several
contributing factors may contribute to these trends.
Firstly, as mentioned above, the vaccine-uptake in the
2010 birth-cohort was noticeably higher than for the
previous birth-cohorts. Theoretically, this could result in
underestimation of the vaccine impact. However, the
hazard ratio of antimicrobial prescription between the
2008 birth-cohort, of which only 1.8% had received > 2
PCV doses, and the 2010 birth-cohort was non-signifi-
cant (HR 1.02 95%CI 0.98–1.06) which suggests that the
18.7% vaccination coverage among children in the 2010
birth-cohort did not introduce significant negative bias
to the vaccine impact estimate. Secondly, inappropriate
prescribing may have decreased during the first half of
the study period, after the Directorate of Health
published new guidelines on diagnosis and treatment of
AOM in 2009 [17]. However, as the majority of Icelandic
doctors go overseas for specialist training (mostly
Sweden, UK and USA), keeping up to date on respective
guidelines and policy after returning back home to
Iceland. This could result in gradual change in behav-
iour, starting prior to implementation, rather than sud-
den change A study comparing outpatient antimicrobial
use in European countries for 2004 and 2009 using
drug-specific quality indicators found that the quality of
antimicrobial prescriptions in Iceland was generally high.
The quality increased between 2004 and 2009, rising in
the European rankings from 12th to 7th place (out of
32) [34]. This may indicate that fewer inappropriate pre-
scriptions were written, thus reducing prescriptions in
general. However, we did not see evidence of increasing
quality of prescriptions during the study period using
the parameters available to us, e.g. proportion of epi-
sodes receiving prescriptions and the proportion of
narrow-spectrum antimicrobials use. To ensure that no
positive bias was introduced due to decreases occurring
prior to vaccine initiation the vaccine impact was calcu-
lated using the last vaccine non-eligible cohort as the
reference, even though 18.7% of those children had re-
ceived > 2 PCV doses.
As previously published by this study group, pneumo-
coccal antimicrobial non-susceptibility is less common
following the introduction of PHiD-CV10 [35], and
fewer children have required parenteral therapy for
AOM [36]. Under these circumstances, one would have
expected the use of narrow spectrum antimicrobials to
increase. However, the opposite was found. In 2013 anti-
microbials classified as second-line penicillins became
the most prevalent antimicrobial class prescribed in
Iceland. The most likely explanation for this is the re-
moval of the amoxicillin suspension from the general
market in Iceland between August 2013 and August
2015. Physicians could still prescribe the amoxicillin
suspension, but it required a written form that was
generally considered a nuisance as compared to the
electronic prescription form to which Icelandic physi-
cians had grown accustomed. Instead of an increased
use of other suspensions within the first-line penicillin
class, such as phenoxymethylpenicillin, the use of
second-line penicillins (amoxicillin/clavulanic acid)
and cephalosporins increased. As amoxicillin/clavula-
nic acid has a higher rate of adverse reactions com-
pared to first line penicillins [37, 38] the removal of
amoxicillin may have resulted in a substantial burden
on children and their parents. In addition, at the end
of the study period and 18 months after the reintro-
duction of amoxicillin into the general market, its use
was still lower than before its removal. This warrants
further investigation.
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Conclusions
The introduction of PHiD-CV10 lead to reduced anti-
microbial use in children, which was mostly due to re-
duced episodes of acute otitis media. This intervention
therefore not only reduces disease burden but could also
slow the spread of antimicrobial resistance.
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